All News

Late-breaker data from EASL Congress 2026 mark a pivotal moment in chronic hepatitis B research.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Three-year trial data show baricitinib sustains and deepens hair, eyebrow, and eyelash regrowth in severe alopecia areata, with stable long-term safety.

Chronic inflammation, hormonal imbalance, and surgical management all deplete ovarian reserve in endometriosis patients, a new systematic review finds.

Structural racism was associated with wider NSCLC survival disparities, with a 10-point Black-White gap in highly segregated counties.

During a White House briefing, Mehmet Oz, MD, discussed the expansion of Trump Rx and crackdowns on duplicate ACA enrollment and fraudulent hospice programs.

Everyday skincare may expose you to microplastics and plastic-linked chemicals tied to skin disease and hormone disruption; dermatologists urge safer products and packaging.

Learn how the Cicada COVID-19 variant spreads, common symptoms, who may be at risk, and what precautions experts recommend.

Coverage denials delay care, drive patients into debt, and erode trust in insurers—yet nearly half of affected patients never appeal.

Surgical therapy for diabetic gastroparesis was associated with meaningful reductions in HbA1c and lower rates of diabetes-related complications.

Acoramidis treatment sustained reductions in all-cause mortality, cardiovascular mortality, and first cardiovascular hospitalization through 54 months.

GLP-1s, care standards updates, nutritional guidance, and AI adoption in diabetes management are just a few of the hot topics to be presented and debated.

OLYMPIA-3 trial at ASCO 2026 shows odronextamab plus CHOP in higher-risk B-cell lymphoma delivers strong MRD-negative CRs with fewer visits.

A post hoc analysis found that worsening symptoms, declining quality of life, and rising NT-proBNP levels frequently precede sudden death in HFmrEF/HFpEF.

The fluocinolone acetonide intravitreal implant showed durable improvements in anatomical and functional outcomes over a follow-up period of 36 months.

Heat-attributable CVD burden could reach 418 DALYs per 100,000 by 2050 under high-emissions scenarios, with low-income counties hit hardest.

Even spending just 5% of income on medical costs raises food insecurity risk by 80% for families with children, study finds.

Manufacturing questions delay review of dexmethylphenidate candidate; no safety or efficacy concerns raised.

The update makes biologics first-line treatment, adds comorbidity management guidance, and aligns practice with evolving European guidelines for psoriasis.

Most patients achieved stable or reduced lesion burden and the treatment was well tolerated by patients.

James F. Howard, MD, discusses what he believes will be the next steps in treating myasthenia gravis.

Trauma after cancer is underdiagnosed and often persists into survivorship, with experts urging trauma-informed screening in oncology care.

As quarantined cruise passengers return home, experts explain Andes hantavirus symptoms, transmission risks, and prevention.

Community oncology practices face major infrastructure and reimbursement gaps when delivering bispecific antibodies.

New CMS Medicaid work requirements could increase employment but may also cause millions of adults to lose coverage by 2027.

Real-world data suggest nirogacestat boosts response in desmoid tumor vs standard-of-care treatment, but small cohorts leave key outcomes unanswered.

Medicare’s GLP-1 Bridge offers temporary coverage for obesity medication at $50/month, but patients face a 2027 cliff as BALANCE stalls.

Abortion costs and Medicaid coverage vary by state, creating financial barriers for patients seeking care after the Dobbs v Jackson decision.